Key Points
- Neil Kumar sold 40,000 shares of BridgeBio on March 12 at an average price of $68.73 for $2.75M, leaving him with 655,686 shares (a 5.75% drop in his stake); he has sold a total of 148,053 shares since Jan. 8, totaling about $10.59M.
- BBIO shares opened near $71.03, sit above the 200‑day moving average ($66.31) but below the 50‑day ($72.92), and the company has a market cap of about $13.77B with a negative P/E.
- Analysts remain broadly positive—23 Buys vs. 1 Sell with a consensus "Moderate Buy" and an average target of $83.95—even as BridgeBio recently missed EPS (-$1.00 vs. -$0.75) while reporting strong revenue growth year‑over‑year.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $68.73, for a total value of $2,749,200.00. Following the completion of the transaction, the chief executive officer owned 655,686 shares of the company's stock, valued at $45,065,298.78. This trade represents a 5.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Neil Kumar also recently made the following trade(s):
- On Thursday, February 19th, Neil Kumar sold 28,053 shares of BridgeBio Pharma stock. The stock was sold at an average price of $71.39, for a total value of $2,002,703.67.
- On Tuesday, February 10th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $71.94, for a total value of $2,877,600.00.
- On Thursday, January 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $73.97, for a total value of $2,958,800.00.
BridgeBio Pharma Trading Up 2.3%
NASDAQ BBIO opened at $71.03 on Tuesday. The business's 50-day moving average price is $72.92 and its 200 day moving average price is $66.31. BridgeBio Pharma, Inc. has a twelve month low of $28.33 and a twelve month high of $84.94. The company has a market capitalization of $13.77 billion, a PE ratio of -18.79 and a beta of 1.13.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. During the same period last year, the business earned ($1.40) EPS. BridgeBio Pharma's revenue for the quarter was up 2521.2% compared to the same quarter last year. Equities analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on BBIO shares. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $88.00 to $98.00 and gave the company an "overweight" rating in a report on Friday, February 13th. Leerink Partners reissued an "outperform" rating and set a $98.00 target price on shares of BridgeBio Pharma in a research report on Thursday. William Blair initiated coverage on shares of BridgeBio Pharma in a report on Tuesday, March 10th. They issued an "outperform" rating on the stock. Barclays reaffirmed an "overweight" rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Finally, Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the stock an "outperform" rating in a research note on Thursday, February 12th. Twenty-three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma has a consensus rating of "Moderate Buy" and an average target price of $83.95.
View Our Latest Report on BBIO
Institutional Investors Weigh In On BridgeBio Pharma
A number of large investors have recently modified their holdings of BBIO. Corient Private Wealth LLC acquired a new stake in BridgeBio Pharma in the second quarter valued at approximately $643,000. WINTON GROUP Ltd acquired a new position in shares of BridgeBio Pharma during the second quarter worth $3,856,000. Principal Financial Group Inc. lifted its position in shares of BridgeBio Pharma by 23.0% during the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company's stock worth $65,829,000 after purchasing an additional 236,885 shares in the last quarter. L & S Advisors Inc purchased a new position in shares of BridgeBio Pharma in the third quarter valued at $877,000. Finally, TD Asset Management Inc purchased a new position in shares of BridgeBio Pharma in the third quarter valued at $4,620,000. Institutional investors and hedge funds own 99.85% of the company's stock.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
